Exclusive: DeepMind’s Demis Hassabis unveils his vision for Isomorphic and AI’s future in biotech

While Demis Hassabis is best known for steering Alphabet’s research efforts in artificial intelligence, the 47-year-old is simultaneously leading a secretive biotech startup looking to bring about an AI revolution in drug discovery.

Hassabis is the CEO of Google DeepMind as well as Isomorphic Labs, an Alphabet-backed company founded in 2021 to take DeepMind’s AI research in biology further into the drug industry. DeepMind has won a myriad of awards for AlphaFold2, its AI system that predicts protein structures and was published in 2021. Headquartered in London, Isomorphic has shared few details about what it’s working on in its roughly two years of existence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Slowing of Peripheral Artery Disease: Another Liraglutide Benefit?

Liraglutide (Victoza), a type 2 diabetes drug, may help prevent peripheral artery disease (PAD) progression, the small, open-label STARDUST trial suggested. Over 6 months, adults

March 14, 2024

Study calls for renaming of ‘obesity’ to better reflect the disease

We must change the way we talk about obesity to improve public understanding of the disease, according to a new study.

July 3, 2023

Therapeutic potential of CD20 x CD3 bispecific antibodies

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of

April 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.